New imaging tools for the diagnosis of infection

Future Microbiology

Volumn 2, Issue 5, 2007, Pages 527-554

  Walker, Ronald C ^a   Jones Jackson, Laurie B ^a   Martin, William ^a   Habibian, M Reza ^a   Delbeke, Dominique ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

18F FDG PET infection imaging; Cytokine imaging; In vivo white cell labeling; Infection imaging; Radiolabeled ciprofloxacin; Radiolabeled white blood cells

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; AVIDIN; BIOTIN; BW 183; BW 250; CHEMOTACTIC PEPTIDE; CIPROFLOXACIN; CYTOKINE; FANOLESOMAB TC 99M; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; GRANULOSCINT; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INDIUM 111; INTERLEUKIN 1; INTERLEUKIN 2; LEUKOTRIENE B4; LIPOSOME; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN; SULESOMAB TC 99M; TECHNETIUM 99M; TECHNETIUM SULFUR COLLOID TC 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIOPHAGE; BONE RADIOGRAPHY; BONE SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC FOOT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIVERTICULITIS; DRUG UPTAKE; FEVER; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; INFECTION; INFLAMMATION; ISOTOPE LABELING; LEUKOCYTE; NONHUMAN; OSTEOMYELITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTHESIS INFECTION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE DISEASE;

ANIMALS; HUMANS; INFECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 35348923612     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.5.527     Document Type: Review

References (173)

1. Rennen HJJM, Boerman OC, Oyen WJG et al.: Imaging Infection/ Inflammation in the new millennium. Eur. J. Nucl. Med. 28, 241-252 (2001).
2. Boerman OC, Rermen H, Oyen WJG et al.: Radiopharmaceuticals to image infection and inflammation. Semin. Nucl. Med. 31, 286-295 (2001).
3. Schauwecker DS: Imaging infection in patients with agranulocytosis. J. Nucl. Med. 43, 925-927 (2002).
4. 99mTc]HMPAO-leukocytes for imaging infection. Semin. Nucl. Med. 24, 110-127 (1994).
5. Datz FL: Indium-II 1-labeled leukocytes for the detection of infection: current status. Semin. Nucl. Med. 24, 92-109 (1994).
6. Datz FL, Thorne DA: Effect of chronicity of infection on the sensitivity of the In-111-labeled leukocyte scan. AJR Am. J. Roentgenol. 147, 809-812 (1986).
7. 99m-Tc-. hexamethylproplyeneamine oxime for labeling leucocytes and imaging inflammation. Lancet 2, 946-949 (1986).
8. 99m HMPAO-labelled leukocytes. Radiology 166, 767-772 (1988).
9. Schmidt KG, Rasmussen JW, Frederiksers PB et al.: Indium-111-granulocyte scintigraphy in brain abscess diagnosis: limitations and pitfalls. J. Nucl. Med. 31, 1121-1127 (1990).
10. 99mTc] HMPAO-leukocytes for imaging infection. Semin. Nucl. Med. 24, 110-127 (1994).
11. McAfee JG, Thakur ML: Survey of radioactive agents for the in vitro labeling of phagocytic leucocytes. I. Soluble agents. II. Particles. J. Nucl. Med. 17, 480-492, (1976).
12. Thakur ML, Lavender JP, Arnot RN et al.: Indlum-111-labeled autologous leukocytes in man. J. Nucl. Med. 18, 1014-1021, (1977).
13. Thakur ML, Coleman RE, Welch MJ: Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J. Lab. Clin. Med. 89, 217-228 (1977).
14. 99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy to the diagnosis of diabetic foot Infection. Eur. J. Nucl. Med., 25, 132-138 (1998).
15. Capriotti G, Chianelli M, Signore A: Nuclear medicine imaging of diabetic foot infection: results of a meta-analysis. Nucl. Med. Commun. 27, 757-764 (2006).
16. 99m sulfur colloid bone marrow imaging for diagnosing musculoskeletal infection. Radiographics 26, 859-870 (2006).
17. 99mTc-markierten monoklonalen Antikörpern: erste klinische Ergebnisse. Nuc. Compact 18, 223-229 (1987).
18. Palestro CJ: In vivo leukocyte labeling: the quest continues. J. Nucl. Med. 48, 332-334 (2007).
19. Gratz S, Braun HG, Behr TM et al.: Photopenia in chronic vertebral osteomyelitis with technetium-99m-antigranulocyte antibody (BW 250/183). J. Nucl. Med. 38, 211-216 (1997).
20. Segarra I, Roca M, Baliellas C et al.: Granulocyte-specific monoclonal antibody technetium-99m-BW 250/183 and indium-111 oxine-labelled leukocyte scintigraphy in inflammatory bowel disease. Eur. J. Nucl. Med. 18, 715-719 (1991).
21. Lipp FW, Wirnsberger GH, Ratschek M et al: The influence of vascular diathesis on the localization of inflammatory foci in renal allografts with a specific antigranulocyte antibody. Eur. J. Nucl. Med. 23, 395-400 (1996).
22. Boubaker A, Delaloye B, Blanc CH et al.: Immununoscintigraphy with antigranuocyte monoclonal antibodies for the diagnosis of septic loosening of hip prostheses. Eur. J Nucl. Med. 22, 139-147 (1995).
23. Klett R, Kordelle J, Stahl U et al.: Immunoscintigraphy of septic loosening of knee endoprosthesis: a retrospective evaluation of the antigranulocyte antibody BW 250/183. Eur. J. Nucl. Med. Mol. Imaging 30, 1463-1466 (2003).
24. Becker W, Dölkemeyer U, Gramatzki M et al.: Use of immunoscintigraphy in diagnosis of fever of unknown origin. Eur. J. Nucl. Med. 20, 1078-1083 (1993).
25. Ryan PJ: Leukoscan for orthopaedic imaging in clinical practice. Nucl. Med. Commun. 23, 707-714 (2002).
26. 99m-labeled monoclonal antigranulocyte antibody. J. Foot Ankle Surg. 42, 2-8 (2003).
27. 99mTc-labeled anti-cd15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. J. Nucl. Med. 41, 449-455 (2000).
28. 99mTc- Anti-CD15 monoclonal antibody (LeuTech) imaging improves diagnostic accuracy and clinical management in patients with equivocal presentation of acute appendicitis. Ann. Surg. 235, 232-239 (2002).
29. 111In-labeled leukocytes - initial experience. Radiology 223, 758-764 (2002).
30. 99mTc-fanolesomab: a new agent for imaging infection and inflammation. Q. J. Nucl. Med. Mol. Imaging 50, 113-120 (2006).
31. Keelan E, Chapman P, Birms R, Peters A, Haskard D: Imaging vascular endothelial activation: an approach using radiolabeled monoclonal antibodies against the endothellal cell adhesion molecule E-selectin. J. Nucl. Med. 35, 276-281 (1994).
32. Jamar F, Chapman PY, Harrison AA, Binns RM, Haskard DO, Peters AM: Inflammatory arthritis: imaging of endothelial cell activation with an In-111 labeled F(ab')2 fragment of anti-E-selection monoclonal antibody. Radiology 194, 843-850 (1995).
33. Bhatti M, Chapman F, Jamar F et al.: Immunolocalization of active inflammatory bowel disease (IBD) using a monoclonal antibody against E-selectin. J. Nucl. Med. 37(Suppl. 5), 114P (1996).
34. Chapman PT, Jamar F, Keelan ET, Peters AM, Haskard DO: Use of a radiolabeled monoclonal antibody against E-selectin for imaging of endothelial activation in rheumatoid arthritis. Arthritis Rheum. 39, 1371-1375 (1996).
35. 99mTc-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Br. J. Radiol. 70, 473-481 (1997).
36. 99m granulocyte antibody scan in inflammatory diseases. Nucl. Med. Commun. 13, 186-192, (1992).
37. Hasler PH, Novak-Hofer I, Blauenstein P et al.: The in vivo binding behavior of an I-123 labeled anti-granulocytes antibody (Granuloszint®). Prog. Clin. Biol. Res. 355, 299-309, (1990).
38. Becker W, Palestro CJ, Winship J et al.: Rapid imaging of infections with a monoclonal antibody fragment (Leukoscan). Clin. Orthrop. 329, 263-272 (1996).
39. 99m-labeled antigranulocyte antibody Fab' fragment. Surgery 125, 288-296, (1999).
40. Harwood SJ, Valdivia S, Hung GL et al.: Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy. Clin. Infect. Dis. 28, 1200-1205, (1999).
41. Thakur ML, Marcus CS, Henneman P et al.: Imaging inflammatory diseases with neutrophil-specific technetium-99m-labeled monoclonal antibody anti-SSEA-1. J. Nucl. Med. 37, 1789-1795 (1996).
42. 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. J. Nucl. Med. 41, 449-455 (2000).
43. 99m-labelled monoclonal antibody. Eur. J. Nucl. Med 15, 361-366 (1989).
44. Becker W, Goldenberg DM, Wolf F: The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions, Semin. Nucl. Med. 24, 142-153 (1994).
45. Fischman AJ, Fucello AJ, Pellegrino-Gensey JL, et al.: Effect of carbohydrate modification on the localization of human polyclonal IgG at focal sites of bacterial infection. J Nucl. Med. 33, 1378-1382 (1992).
46. Oyen WJG, Claessens RAMJ, Raemaekers JMM, de Pauw BE, van der Meer JWM, Corstens FHM: Diagnosing infection in febrile granulocytopenic patients with indium-111 labeled human IgG. J. Clin. Oncol. 10, 61-68 (1992).
47. Buscombe JR, Oyen WJG, Grant A et al.: Indium-111-labeled human polyclonal immunoglobulin: identifying focal infection in-patients positive for human immunodeficiency virus (HIV). J. Nucl. Med. 34, 1621-1625 (1993).
48. Nijhof MW, Oyen WJ, van Kampen A, Claessens RA, van der Meer JW, Corstens FHM: Evaluation of infections of the locomotor system with indium-111-labelled human IgG scintigraphy. J. Nucl. Med. 38, 1300-1305 (1997).
49. 99mTc-HMPAO labelled leukocytes in inflammatory bowel disease. Eur. J. Nucl. Med. 22, 664-670 (1995).
50. 99m labeled to human immunoglobulin G through the nicotinyl hydrazine derivative: a clinical study. J. Nucl. Med. 39, 119-1124 (1998).
51. Zoghbi S, Thakur M, Gottschalk A: Selective cell labelling: a potential radioactive agent for labeling of human neutrophils. J. Nucl. Med. 22, 32P (1981).
52. Fischman AJ, Pike MC, Kroon D et al.: Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs. J. Nucl. Med. 32, 483-491 (1991).
53. 99m labeled chemotactic peptides: comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. J. Nucl. Med. 34, 2176-2181 (1993).
54. Fischman AJ, Rauh D, Solomon H et al.: In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. J Nucl. Med. 34, 2130-2134 (1993).
55. 99m labelled chemotactic peptides: analogues with reduced neutropenia. Nucl. Med. Commun. 17, 132-139 (1996).
56. Babich JW, Dong Q, Graham W et al.: A novel high affinity chemotactic peptide antagonist for infection imaging. J. Nucl. Med. 38, 268P (1997).
57. 99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur. J. Nucl. Med. 27, 292-301 (2000).
58. 99mubiquicidin 29-41 as human infection-imaging agent: clinical trial. J Nucl. Med. 46, 567-573 (2005).
59. 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections. Eur. J Nucl. Med. Mol. Imaging 34, 1302-1309 (2007).
60. Zijlstra S, Gunawan J, Freytag C, Burchert W: Synthesis and evaluation of fluorine-18 labelled compounds for imaging of bacterial infections with PET. Appl. Radiat. Isot. 64, 802-807 (2006).
61. 99mTc-labeled LTB4 antagonist. J. Nucl. Med. 46, 1546-1551 (2005).
62. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J. Nucl. Med. 42, 788-794 (2001).
63. 99mTc-UBI 29-41 for imaging of bacterial infections. Nucl. Med. Biol. 29, 413-422 (2002).
64. Lupetti A, Welling MM, Pauwels EK, Nibbering PH: Radiolabelled antimicrobial peptides for infection detection. Lancet Infect. Dis. 3, 223-229 (2003).
65. 99mTc-UBI specificity for bacteria. Nucl. Med. Biol. 30, 597-603 (2003).
66. 99mTc-UBI 29-41 in humans. Nucl. Med. Biol. 31, 373-379 (2004).
67. 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41. Nucl. Med. Biol. 31, 503-509 (2004).
68. van der Laken CJ, Boerman OC, Oyen WJG et al.: Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. Eur. J. Nucl. Med. 22, 1249-1255 (1995).
69. van der Laken CJ, Boerman OC, Oyen WJG et al.: Preferential localization of systemically administered radiolabeled interleukin-1α in experimental inflammation in mice by binding to the type II receptor. J. Clin. Invest. 100, 2970-2976 (1997).
70. Barrera P, van Der Laken CJ, Boerman OC et al.: Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology 39, 870-874 (2000).
71. 123I-interleukin-2 labeling procedure and animal studies. Nucl. Med. Commun. 13, 713-722 (1992).
72. 99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl. Med. Biol. 24, 579-586 (1997).
73. Signore A: Interleukin-2 scintigraphy: an overview. Nucl. Med. Commun. 20, 938 (1999).
74. Signore A, Chianelli M, Annovani A et al.: Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur. J. Nucl. Med. 27, 18-24 (2000).
75. 123I-interleukin-2 scintigraphytigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J. Nucl. Med. 41, 242-249 (2000).
76. Hay RV, Skinner RS, Newman OC et al.: Scintigraphy of acute inflammatory lesions in rats with radiolabelled recombinant human interleukin-8. Nucl. Med. Commun. 18, 367-378 (1997).
77. Gross MD, Shapiro B, Skinner RS, Shreve P, Fig LM, Hay RV: Scintigraphy of osteomyelitis in man with human recombinant interleukin-8. J. Nucl. Med. 37, 25P (1996).
78. 99m-labeled interleukin-8. J. Nucl. Med. 42, 117-122 (2001).
79. 99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J. Nucl. Med. 48, 337-343 (2007).
80. 99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J. Nucl. Med. 37, 673-679 (1996).
81. r(1999).
82. Hnatowich D, Virzi F, Rusckowski M: Investigation of avidin and biotin for imaging investigation. J. Nucl. Med. 28, 1294-1302 (1987).
83. Samuel A, Paganelli G, Chiesa R et al.: Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J. Nucl. Med. 37, 55-61 (1996).
84. Rusckowski M, Paganelli, Hnatowich D et al.: Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. J. Nucl. Med. 37, 1655-1662 (1996).
85. 99mTc-labeled bacteriophage as a potential infection-specific imaging agent. J. Nucl. Med. 45, 1201-1208 (2004).
86. 111In to image focal infection in rats. J. Nucl. Med. 36, 1639-1644 (1995).
87. Laverman P, Dams ETM, Oyen WJG et al.: A novel method to label liposomes with Tc-99m via the hydrazinonicotinyl derivative: a comparison with Tc-99m-HMPAO labeled PEG-liposomes. J. Nucl. Med. 40, 192-197 (1999).
88. 99m-PEG-liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J. Nucl. Med. 41, 622-630 (2000).
89. Anderson VE, Osheroff N: Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 7, 339-355 (2001).
90. 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 347, 233-235 (1996).
91. 99m ciprofloxacin (Infecton) imaging in suspected orthopaedic infection: a comparison with sequential bone/gallium imaging. Eur. J. Nucl. Med. 28, 822-830 (2001).
92. 99mTc-ciprofloxacin (Infecton). J. Clin. Pathol. 55, 817-823 (2002).
93. 99m white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl. Med. Commun. 23, 655-661 (2002).
94. 18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur. J. Nucl. Med. Mol. Imaging 32, 143-150 (2005).
95. 99mTc-HMPAO leukocyte scintigraphy. J. Nucl. Med. 42, 567-574 (2001).
96. 99m Infecton for the localisation of bacterial infection. Eur. J. Nucl. Med. 24, 553-556 (1997).
97. 99mTc-Ciprofloxacin (Infecton) imaging in the diagnosis of knee prosthesis infections. Nucl. Med. Commun. 23, 167-170 (2002).
98. 99mTc-Infecton, a novel agent for detecting sites of infection. J. Clin. Pathol. 51, 215-219 (1998).
99. 99mTc-ciprofloxacin (Infecton). J. Clin. Pathol. 55, 817-823 (2002).
100. 99mTc-ciprofloxacin. J. Nucl. Med. 45, 2008-2094 (2004).
101. Dumarey N, Blocklet D, Appelboom T, Tant L, Schoutens A: Infecton is not specific for bacterial osteo-articular infective pathology. Eur. J. Nucl. Med. 29, 530-535 (2002).
102. 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J. Nucl. Med. 44, 920-926 (2003).
103. 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases (Letter to the Editor). J. Nucl. Med. 45, 922-923 (2004).
104. 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases (Letter to the Editor). J. Nucl. Med. 45, 923 (2004).
105. Pauwels EKJ, Welling MM, Lupetti A, Paulusma-Annema A, Nibbering PH: Balter HS. Letter to the editor. Eur. J. Nucl. Med. 27, 1866-1868 (2000).
106. 99mTc-labelled ciprofloxacin for infection detection. Letter to the Editor. Eur. J. Nucl. Med. 28, 781 (2001).
107. 99mTc-labelled ciprofloxacin for infection detection. Response - Letter to the Editor. Eur. J. Nucl. Med. 28, 781 (2001).
108. 99mTc-ciprofloxacin. J. Nucl. Med. 45, 2088-2094 (2004).
109. 99mTc-ciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J Nucl. Med. 43, 239-245 (2002).
110. 99mTc-cefoperazone complex, a novel agent for detecting sites of infection. J. Radioanalyt. Nucl. Chem. 272, 197-171 (2007).
111. Stumpe KDM, Dazzi H, Schaffner A, von Schulthess GK: Infection imaging using whole-body FDG-PET. Eur. J. Nucl. Med. 27, 822-832 (2000).
112. 18F-FDG PET/CT. J. Nucl. Med. 46, 444-449 (2005).
113. 18F]-fluoro-D-glucose positron emission tomography (FDG-PET) in an animal model. J. Orthop. Res. 23, 1484-1489 (2005).
114. 18F]fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl. Med. Commun. 25, 819-823 (2004).
115. 18F] fluoro-D-glucose by fungal-associated inflammation: the standardized uptake value is greater for lesions of blastomycosis than for lymphoma in dogs with naturally occurring disease. Mol. Imaging Biol. 4(3), 201-207 (2002).
116. 18F] fluoro-D-glucose by fungal-associated inflammation: the differential uptake ratio for blastomyces-associated lesions is as high as for lymphoma and higher than for turpentine abscesses in experimentally induced lesions in rats. Mol. Imaging Biol. 4(3), 193-200 (2002).
117. 125I-HSA. Eur. J. Nucl. Med. 26, 333-341 (1999).
118. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J. Clin. Oncol. 23, 7957-7963 (2005).
119. 99mTc-sulfur colloid marrow imaging. J. Nucl. Med. 45, 1864-1871 (2004).
120. 18F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl. Med. Commun. 23, 645-653 (2002).
121. 18F-FDG PET in detecting infected lower limb prosthesis implants. J. Nucl. Med. 42, 44-48 (2001).
122. Schiesser M, Stumpe KD, Trentz O, Kossmann T, Von Schulthess GK: Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. Radiology 226, 391-8 (2003).
123. Meller J, Koster G, Liersch T et al.: Chronic bacterial osteomyelitis: prospective comparison of (18)F-FDG imaging with a dual-head coincidence camera and (111)In-labelled autologous leucocyte scintigraphy. Eur. J. Nucl. Med. Mol. Imaging 29, 53-60 (2002).
124. Reinartz P, Mumme T, Hermanns B et al.: Radionuclide imaging of the painful hip arthroplasty: positron-emission tomography versus triple-phase bone scanning. J. Bone Joint Surg. (Br) 87(4), 465-470 (2005).
125. 111In-oxine-labeled leukocytes for detection of infection. Radiology 238, 978-987 (2006).
126. 18F-FDG-labeled leukocyte PET/CT initial experience in 21 patients. J. Nucl. Med. 47, 625-632 (2006).
127. De Winter F, Van de Wiele C, Vogelaers D et al.: Fluorine-18 fluorodeoxyglucose-positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. J. Bone Joint Surg. Am. 83, 651-600 (2001).
128. 99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J. Nucl. Med.. 39, 2145-52 (1998).
129. Chacko TK, Zhuang H, Stevenson K et al.: The importance of the location of fluorodeoxyglucose uptake in periprosthetic infection in painful hip prostheses. Nucl. Med. Commun. 23, 851-855 (2002).
130. 18F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl. Med Commun. 23, 645-653 (2002).
131. 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur. J. Nucl. Med. Mol. Imaging 34, 704-714 (2007).
132. Termaat MF, Raijmakers PGHM, Scholten HJ et al.: The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J. Bone Joint Surg. Am. 87, 2464-2471 (2005).
133. Petersdorf RG: Fever of unknown origin: an old friend revisited. Arch. Intern. Med. 152, 21-22 (1992).
134. Durack DT, Street AC: Fever of unknown origin - reexamined and redefined. Curr. Clin. Top. Infect. Dis. 11, 35-51 (1991).
135. Vanderschueren S, Knockaert D, Adriaenssens T et al.: From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch. Intern. Med. 12, 1033-1041 (2003).
136. Cunha BA: Fever of unknown origin. Infect. Dis. Clin. North Am. 10, 111-127 (1996).
137. Bleeker-Rovers CP, de Kleijn EMHA, Corstens F et al.: Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur. J. Nucl. Med. Mol. Imaging 31, 29-37 (2004).
138. Jaruskova M and Belohlaek O: Role of FDG-PET and PET/CT in the diagnosis of prolonged febrile states. Eur. J. Nucl. Med. Mol. Imaging 33, 913-918 (2006).
139. Bleeker-Rovers CP, Vos FJ, Mudde AH et al.: A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur. J. Nucl. Med. Mol. Imaging 34, 694-703 (2007).
140. 18F-FDG PET and PET/CT in fever of unknown origin. J. Nucl. Med. 48, 35-45 (2007).
141. 18F-FDG PET/CT. J. Nucl. Med. 48, 1230-1236 (2007).
142. Annovazzi A, Bagni B, Burroni L, D'Alessandria C, Signore A: Nuclear medicine imaging of inflammatory/infective disorders of the abdomen. Nucl. Med. Commun.. 26, 657-664 (2005).
143. Capriotti G, Chianelli M, Signore A: Nuclear medicine imaging of diabetic foot infection: results of meta-analysis. Nucl. Med. Commun. 27, 757-764 (2006).
144. Prandini N, Lazzeri E, Rossi B, Erba P, Pariselia MG, Signore A: Nuclear medicine imaging of bone infections. Nucl. Med. Commun. 27, 633-644 (2006)
145. 99mTc-HMPAO-labeled leukocyte scintigraphy for bone and joint infections. J. Nucl. Med. 47, 1908-1913 (2006).
146. Burroni L, D'Alessandria C, Signore A: Diagnosis of vascular prosthesis infection: PET or SPECT? J. Nucl. Med. 48, 1227-1229 (2007).
147. Stumpe KD, Dazzi H, Shaffner A, Von Schulthess GH: Infection imaging using whole-body FDG PET. Eur. J. Nucl. Med. 27, 822-832 (2000).
148. Chacko TK, Zhuang H, Nakhoda KZ, Moussavian B, Alavi A: Application of fluorodeoxyglucose positron emission tomography in the diagnosis of infection. Nucl. Med. Commun. 24, 615-624 (2003).
149. Jaruskova M, Belohlavek O: Role of FDG-PET and PET/CT in the diagnosis of prolonged febrile states. Eur. J. Nucl. Med. Mol. Imaging 33, 913-918 (2006).
150. 18F]fluoro-D-glucose for the evaluation of suspected infected vascular graft. Mol. Imaging Biol. 5, 23-25 (2003).
151. Krupnick AS, Lombardi JV, Engels FH et al.: 18-Fluorodeoxyglucose positron emission tomography as a novel imaging tool for the diagnosis of aortoenteric fistula and aortic graft infection: a case report. Vasc. Endovascular Surg. 37, 363-366 (2003).
152. Stádler P, Belohlávek O, Spacek M, Michálek P: Diagnosis of vascular prosthesis infection with FDG-PET/CT. J. Vasc. Surg. 40, 1246-1247 (2004).
153. Fukuchi K, Ishida Y, Higashi M et al.: Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. J. Vasc. Surg. 42, 919-925 (2005).
154. Tsunekawa T, Ogino H, Minatoya K, Matsuda H, Sasaki H, Fukuchi K: Masked prosthetic graft to sigmoid colon fistula diagnosed by 18-fluorodeoxyglucose positron emission tomography. Eur. J. Vasc. Endovasc. Surg. 33, 187-189 (2007).
155. Tegler G, Sorensen J, Bjorck M, Savitcheva I, Wanhainen A: Detection of aortic graft infection by 18-fluorodeoxyglucose positron emission tomography combined with computed tomography. J. Vasc. Surg. 45, 828-830 (2007).
156. 18F-FDG PET/CT. J. Nucl. Med. 48, 1230-1236 (2007).
157. Tyrrell PNM, Cessar-Pullicino VN, McCall IW: Spine Infection. Eur. Radiol. 9, 1066-1077 (1999).
158. 99m-methylene diphosphonate bone scintigraphy: J. Nucl. Med. 32, 1861-1865 (1991).
159. Wukich DK, Abreu SH, Callaghan JJ et al.: Diagnosis of infection by preoperative scintigraphy with indium-labeled leukocytes. J. Bone Joint Surg. Am. 69, 1353-1360 (1987).
160. Schauwecker DS: Osteomyelitts: diagnosis with In-111-labeled leukocytes. Radiology 171, 141-146 (1989).
161. Mok YP, Carney WH, Fernandez-Ulloa M: Skeletal photopenic lesions in In-111-WBC imaging. J. Nucl. Med. 25, 1322-1326 (1984).
162. Brown ML, Hauser MF, Aznarez A, Fitzgerald RH: Indium-111-leukocyte imaging: the skeletal photopenic lesion. Clin. Nucl. Med. 11, 611-613 (1985).
163. Datz FL, Thorne DA: Cause and significance of cold bone defects on indium-111-labeled leukocyte imaging. J. Nucl. Med. 28, 820-823 (1987).
164. Wukich DK, Van Dam B, Abreu SH: Preoperative indium-labeled white blood cell scintigraphy in suspected osteomyelitis of the axial skeleton. Spine 13, 1168-1170 (1988).
165. Whalen JL, Brown ML, McCleod R, Fitzgerald RH: Limitations of Indium leukocyte imaging for the diagnosis of spine infections. Spine 16, 193-197 (1991).
166. Eisenberg B, Power JE, Alavi A: Cold defects in In-111-labeled leukocyte imaging of osteomyelitis in the axial skeleton. Clin. Nucl. Med. 16, 103-106 (1991).
167. Stumpe KD, Zanetti M, Weishaupt D et al.: FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. Am. J. Rheumatol. 179, 1151-1157 (2002).
168. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur. J. Nucl. Med. 29, 516-524 (2002).
169. 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur. J. Nucl. Med. Mol. Imaging 34, 704-714 (2007).
170. Zhuang H, Sam JW, Chacko TK et al.: Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur. J. Nucl. Med. Mol. Imaging 30, 1096-1103 (2003).
171. Gemmel F, Dumarey N, Palestro CJ: Radionuclide imaging of spinal infections. Eur. J. Nucl. Med. Mol. Imaging 33 1226-1237 (2006).
172. Liu RS, Chu LS, Yen SH et al.: Detection of anaerobic ondontogenic infections by fluorine- 18 fluoromisonidazole. Eur. J. Nucl. Med. Mol. Imaging 23, 1384-1387 (1996).
173. Oyen WJG, Corstens FHM, Boerman OC: Discriminating infection from sterile inflammation: can radiolabeled antibiotics solve the problem? Eur. J. Nucl. Med. Mol. Imaging 32, 151-152 (2005).